What does this research mean for the field?

A newly developed, cost-efficient single-molecule molecular inversion probe (smMIP)-based next-generation sequencing assay for measurable residual disease (MRD) detection independently predicts inferior overall survival in acute myeloid leukemia patients prior to allogeneic stem cell transplantation. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to evaluate the effectiveness of an affordable NGS-based MRD assay for predicting patient outcomes in AML post-transplantation.

May 30, 2026HaematologicaOpen Access

Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

View Full Paper

Ask AI

Bookmark

Authors

SKSimon M. Krauß THTara Holloway AWAnne Weigert

Discussion

Member takes

Overview

Randomized trial shows that NGS-based MRD detection predicts outcomes in AML patients undergoing allo-SCT, indicating clinical relevance.

Key Points

This research aims to evaluate the effectiveness of an affordable NGS-based MRD assay for predicting patient outcomes in AML post-transplantation.
Developed a cost-efficient NGS MRD assay using single-molecule molecular inversion probes targeting 92 genomic loci in 33 AML driver genes.
Applied the assay to 93 AML patients in remission before allo-SCT.
Defined MRD positivity as ≥ 1 non-DTA gene variant with ≥ 0.5% variant allele frequency.
MRD positivity was associated with significantly shorter post-transplant overall survival (OS; p < 0.001).
NGS-based MRD detection was an independent predictor of inferior OS (hazard ratio 4.58; p = 0.002).
Conditioning intensity did not impact outcomes for MRD-positive patients.

Cite This Study

Krauß et al. (2026) studied this question.

synapsesocial.com/papers/6a1a827f0307b785094341c1 https://doi.org/10.3324/haematol.2025.300432

View Full Paper

Ask AI

Bookmark

May 30, 2026HaematologicaOpen Access

Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

View Full Paper

Ask AI

Bookmark

Authors

SKSimon M. Krauß THTara Holloway AWAnne Weigert

Discussion

Member takes

Overview

Randomized trial shows that NGS-based MRD detection predicts outcomes in AML patients undergoing allo-SCT, indicating clinical relevance.

Key Points

This research aims to evaluate the effectiveness of an affordable NGS-based MRD assay for predicting patient outcomes in AML post-transplantation.
Developed a cost-efficient NGS MRD assay using single-molecule molecular inversion probes targeting 92 genomic loci in 33 AML driver genes.
Applied the assay to 93 AML patients in remission before allo-SCT.
Defined MRD positivity as ≥ 1 non-DTA gene variant with ≥ 0.5% variant allele frequency.
MRD positivity was associated with significantly shorter post-transplant overall survival (OS; p < 0.001).
NGS-based MRD detection was an independent predictor of inferior OS (hazard ratio 4.58; p = 0.002).
Conditioning intensity did not impact outcomes for MRD-positive patients.

Cite This Study

Krauß et al. (2026) studied this question.

synapsesocial.com/papers/6a1a827f0307b785094341c1 https://doi.org/10.3324/haematol.2025.300432

View Full Paper

Ask AI

Bookmark